In episode 330, Mike and James do a PREMIUM job of looking at 2 important new publications about medications for type 2 diabetes. We look at an RCT of semaglutide that actually shows a benefit. We then look at a very thorough systematic review/meta-analysis of all the studies and publications around T2DM since 1998. The results demonstrate very clearly that the evidence doesn’t really support what is being written in the diabetes clinical practice guidelines.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
N Engl J Med 2016; 375:1834-44
2) Glycemic Control for Patients With Type 2 Diabetes Mellitus Our Evolving Faith in the Face of Evidence
Circ Cardiovasc Qual Outcomes. 2016;9:00-00. DOI: 10.1161/CIRCOUTCOMES.116.002901.